Please login to the form below
Trajenta
This page shows the latest Trajenta news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolsters NASH pipeline with $870m Yuhan deal
Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo
Latest news
-
Boehringer Ingelheim calls for "strong and united" Europe
In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to
-
The Global Awards 2016 finalists announced
Sudler &Hennessey London's diabetes iPad game, 'The Journey Ahead Challenge' for Trajenta EASD Congress Activity also made the cut. ... The campaign saw players earn 'fuel' in the driving game by answering questions about diabetes and Trajenta's brand.
-
Boehringer Ingelheim returns to growth after US turnaround
Sales of DPP-4 inhibitor Trajenta (linagliptin) and its Jentadueto (linagliptin and metformin) combination rose 42.9% to 909m. ... The company will not publish separate sales figures for Trajenta and Jentadueto until next year, but said 2015's
-
Langland and CAHG take top prizes at Best of Health Awards
Healthcare Professional - Digital Media. 'The Road Ahead Challenge' for Trajenta, by Sudler London .
-
Boehringer returns to growth in first half
1% increase to reach 5.4bn thanks to higher sales of its Trajenta (linagliptin) franchise. ... Trajenta and combination product Jentadueto (linagliptin and metformin) climbed 22% to 419m in the six-month period, although this growth rate is well below
More from news
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Market dynamics, marketing and analytics
Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... The key points here are that Trajenta is used by just under 8, 000 practices but appears to have
-
Interview: Beate Wieseler, IQWIG
This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).
-
Interview: Allan Hillgrove, Boehringer
The launch of Trajenta has been positive in many markets around the world. ... reimbursement body IQWIG refusing to recommend several new drugs, including Boehringer's diabetes treatment Trajenta.
-
A new dogma in HTA assessment
Ingelheim and Eli Lilly's Type 2 diabetes drug Trajenta (linagliptin).
-
Country report: The healthcare market in Germany
6. Less than comparator. It is significant that last year, BI and Lilly decided not to launch their new diabetes drug Trajenta in Germany, blaming price controls. ... Out of the 10 products assessed last year, four have obtained poor innovation scores:
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- Armoured CAR ‘could overwhelm solid tumour resistance’
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
- Realising the potential of omnichannel in medical communications
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
